ICU Medical, Inc. (NASDAQ:ICUI) Just Reported And Analysts Have Been Cutting Their Estimates

Shareholders might have noticed that ICU Medical, Inc. (NASDAQ:ICUI) filed its quarterly result this time last week. The early response was not positive, with shares down 2.4% to US$138 in the past week. Revenues of US$599m beat expectations by a respectable 4.4%, although statutory losses per share increased. ICU Medical lost US$0.63, which was 37% more than what the analysts had included in their models. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on ICU Medical after the latest results.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Taking into account the latest results, the current consensus, from the five analysts covering ICU Medical, is for revenues of US$2.20b in 2025. This implies a not inconsiderable 9.0% reduction in ICU Medical's revenue over the past 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 62% to US$1.46. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$2.41b and losses of US$0.49 per share in 2025. While this year's revenue estimates dropped there was also a very substantial increase in loss per share expectations, suggesting the consensus has a bit of a mixed view on the stock.

See our latest analysis for ICU Medical

There was no major change to the consensus price target of US$185, signalling that the business is performing roughly in line with expectations, despite lower earnings per share forecasts. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values ICU Medical at US$197 per share, while the most bearish prices it at US$175. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that revenue is expected to reverse, with a forecast 12% annualised decline to the end of 2025. That is a notable change from historical growth of 16% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 8.2% annually for the foreseeable future. It's pretty clear that ICU Medical's revenues are expected to perform substantially worse than the wider industry.

The Bottom Line

The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at ICU Medical. On the negative side, they also downgraded their revenue estimates, and forecasts imply they will perform worse than the wider industry. The consensus price target held steady at US$185, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for ICU Medical going out to 2027, and you can see them free on our platform here.

It is also worth noting that we have found 1 warning sign for ICU Medical that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.